CVRx (CVRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Jun, 2026Opening remarks and agenda
Meeting commenced at 10 A.M. Central Time with all board members and the independent auditor present.
Notice of the meeting was sent to stockholders on April 20, 2026.
Stockholders could vote or change votes during the meeting and submit questions electronically.
Board and executive committee updates
Three class 2 directors were up for election for a three-year term.
Michael Dale, Joseph Slattery, and Kevin Hykes were elected as directors by plurality vote.
Corporate governance
Quorum was established with a majority of outstanding shares represented.
Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Jared Oasheim, CFO, served as inspector of elections and certified the voting.
Latest events from CVRx
- Barostim therapy gains momentum with expanded access, strong evidence, and accelerating U.S. growth.CVRX
Goldman Sachs 47th Annual Global Healthcare Conference 202611 Jun 2026 - Barostim's clinical success and new coverage drive heart failure market expansion and access.CVRX
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Q1 2026 revenue rose 20% with strong U.S. growth, margin gains, and market expansion efforts.CVRX
Q1 202612 May 2026 - Votes are sought for three director nominees and auditor ratification at the 2026 annual meeting.CVRX
Proxy filing20 Apr 2026 - Annual meeting to elect directors, ratify auditor, and address governance and compensation.CVRX
Proxy filing20 Apr 2026 - 2025 revenue up 10%, margins improve, and 2026 outlook projects continued growth.CVRX
Q4 202512 Feb 2026 - Q2 revenue up 24% to $11.8M; net loss widens, full-year outlook raised.CVRX
Q2 20242 Feb 2026 - Barostim delivers breakthrough heart failure therapy, targeting a $2.2B U.S. market with strong results.CVRX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Barostim targets a large unmet heart failure need with strong growth, evidence, and leadership focus.CVRX
The 44th Annual William Blair Growth Stock Conference1 Feb 2026